Mersana to collaborate with Merck KGaA to develop ADCs

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

Ipsen and Sutro Biopharma formed an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate in the final stages of preclinical development which targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.

April 05, 2024

Vol.50 No.14

In Brief

Jill DeSimone joins Swim Across America’s board of directors

Jill DeSimone, a global pharmaceutical executive, joined Swim Across America’s board of directors.

February 23, 2024

Vol.50 No.08

Drugs & Targets

U.S. Patent Office grants patent for ATOR-4066 bispecific antibody cancer treatment

The United States Patent and Trademark Office, or USPTO issued U.S. Patent No. US 11,873,348 covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.

January 19, 2024

Vol.50 No.03

Clinical Roundup

Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

Merck and Moderna Inc. have initiated the phase III randomized INTerpath-002 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda as adjuvant treatment in patients with completely resected (R0) Stage II, IIIA or IIIB (with nodal involvement [N2]) non-small cell lung cancer.

January 05, 2024

Vol.50 No.01

Clinical Roundup

Merck’s Welireg reached primary endpoint of PFS in phase III trial for RCC

In a prespecified interim analysis of the phase III LITESPARK-005 trial, Welireg, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, showed a statistically significant and clinically meaningful improvement in progression-free survival compared to Afinitor (everolimus) in adult patients with advanced renal cell carcinoma that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor therapies.

September 08, 2023

Vol.49 No.33

Drugs & Targets

EC approves Keytruda + trastuzumab + chemo for first-line treatment of GEJ cancer

The European Commission approved Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.

September 08, 2023

Vol.49 No.33

Mersana to collaborate with Merck KGaA to develop ADCs

YOU MAY BE INTERESTED IN

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

Jill DeSimone joins Swim Across America’s board of directors

U.S. Patent Office grants patent for ATOR-4066 bispecific antibody cancer treatment

Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

Merck’s Welireg reached primary endpoint of PFS in phase III trial for RCC

EC approves Keytruda + trastuzumab + chemo for first-line treatment of GEJ cancer

Renew today!

Subscriber content

Login